12:00 AM
 | 
Feb 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Proleukin Aldesleukin: Final Phase III data

In the open-label, international Phase III SILCAAT trial, Proleukin plus antiretroviral therapy significantly increased CD+ T cell counts by 57 cells/mm 3 vs. antiretroviral therapy alone (p<0.001), but that did not translate into reduced risk of HIV-associated opportunistic diseases or death, which was the primary endpoint (2.06 vs. 2.17 events/100 person-years, p=0.7). The trial also did not meet the secondary...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >